Background: Tuberculosis (TB) is a chronic bacterial disease, which despite the presence of effective drug strategies, still remains a serious health problem worldwide. Estimation of survival rate is an appropriate indicator for prognosis in patients with pulmonary TB. Therefore, this research was designed with the aim of accurate estimation of the survival of patients by taking both the death event and relapse into consideration. Materials and Methods: Based on a retrospective cohort study, information of 2,299 patients with pulmonary TB that had been referred to and treated in Masih Daneshvari Hospital from 2005 to 2015 was reviewed. To estimate the survival of patients with pulmonary TB, the competing risks model, which considered death and relapse as competing events, was used. In addition, the effect of factors affecting the cumulative incidence function (CIF) of death event and relapse was also examined. Results: The effect of risk factors on the CIF of death events and relapse showed that patients' age, marital status, contact with TB patients, adverse effect of drugs, imprisonment and HIV positivity were factors that affected the CIF of death. Meanwhile, sex, marital status, imprisonment and HIV positivity were factors affecting the CIF of relapse (P <0.05). Considering death and relapse as competing events, survival estimation in pulmonary TB patients showed that survival in this group of patients in the first, third, fifth and tenth year after treatment was 39%, 14%, 7% and 0%, respectively. Conclusion: The use of competing risks model in survival analysis of patients with pulmonary TB with consideration of competing events, enables more accurate estimation of survival.
INTRODUCTION

Tuberculosis is a chronic bacterial disease caused by
Mycobacterium tuberculosis (M. tuberculosis,) belonging to genus Mycobacteriaceae (1) .
For a long time, TB was proposed as one of the leading causes of morbidity and mortality. Nowadays, this disease is still one of the most serious health problems in the world, despite the discovery of the causative agent, vaccine and effective drug Association of TB with certain diseases such as diabetes mellitus and HIV increases the risk of progression of infection to active disease. Also, HIV infection greatly increases the risk of active TB, such that about one-third of HIV deaths globally are due to TB (6) (7) (8) (9) (10) (11) (12) . Iran with a TB incidence of 21 persons/100,000 and mortality rate of 3 to 10%, is among countries with medium incidence and low mortality and morbidity rates of TB (13, 14) .
One of the most important indicators of prognosis after diagnosis and treatment of pulmonary TB patients is increase in the patients' survival rate, particularly 5-year survival rate. Various methods have been designed, which estimate the survival rate of patients with pulmonary TB.
The most common models are standard survival models (methods such as Kaplan -Meier and survival regression models) (15) (16) (17) . As these methods only evaluate the time until death event, the chance of being able to identify other factors (besides death) that can influence patients' survival is non-existent (18, 19) .
Another statistical model designed to solve such a problem is called competing risks model. Based on this model, the patients during the study experience various events such as death or relapse; the time for reaching any of these events and factors affecting it play essential role in patient survival (18, 20) . With the exception of death, events such as disease relapse (that are often called competing events) have led to the design of modern approaches in survival studies. In such cases, the natural course of the disease can be considered as a stochastic process, during which the patients may be exposed to different events (18, 21, 22) . Competing risks models consider the occurrence of more events (except death) for patients during the study. Therefore, it offers a more accurate estimation of patients' survival in comparison to the standard models (23, 24) . These models are used whenever there is the possibility of occurrence of events besides death in patients during the study.
Very few studies have been performed on the survival of patients with pulmonary TB. Unfortunately most of the studies conducted were based on survival standard models focusing only on the death event (25) (26) (27) (28) (29) 
MATERIALS AND METHODS
Based on a retrospective cohort study, information of 2,299 TB patients that had been referred to and treated at the NRITLD, Masih Daneshvari Hospital, from 2005 to 2015, was collected. The data were obtained from patient records present in hospital archives with address and phone number for later follow-up. "TB death" was specified for all those TB patients, in whom TB was mentioned as the cause of death in the medical records.
Meanwhile "non TB related death" was allocated to any TB patient who had died as a result of non-TB related causes. Estimation of CIF of death event and disease relapse in Table 1 showed that with passage of time, the probability of death event in patients with pulmonary TB increased.
The probability of death event in patients with pulmonary TB was 0.56 one year after treatment and 0.82 and 0.8 at 5
and 10 years after treatment, respectively. In other words, 5
and 10 years after treatment the probability of death event as the first event was 82% and 88%, respectively. This shows that the probability of death event in the first 5 years after treatment is more than that in the second 5 years after treatment ( Figure 1 ).
Based on the results of this study, the event of disease relapse occurred slower as compared to death and the probability of disease relapse increased during the 3 years after treatment in patients with pulmonary TB. In other words, the probability of disease relapse event is 0.05 in the first year after treatment and 0.10 in the third year after treatment; the probability of disease relapse event remains almost constant thereafter (Figure 1 ). In fact, as the first event, the probability of disease relapse event one year and three years after treatment is 5% and 10%, respectively.
While considering disease relapse and death as competing events, TB patients' survival estimation showed that the survival of these patients in the first, third, fifth and tenth year after treatment was 0.39, 0.14, 0.07 and 0.00, respectively. Thus, the probability that a patient with treated pulmonary TB does not relapse or die after 5 years is 7%; however, almost all patients showed disease relapse or expired after 10 years (Table 1) . HIV positivity increased the probability of death event and variables of TB contact and imprisonment reduced the probability of death event. The results also showed that variables of male gender, marital status and HIV positivity reduced the probability of relapse event and only imprisonment increased the probability of relapse event (Table 2 ). 
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DISCUSSION
In this study, using competing risks method and taking into account the competing events of death and relapse, 10-year survival of patients with pulmonary TB during treatment was surveyed. Based on the results of this study, survival estimation of one, three and five-years in these patients during treatment was 39%, 14% and 7%, respectively. These values were less as compared with survival estimation in the first five-years in many studies conducted in other countries (25) (26) (27) (28) (29) .
The present study is the first study on 10-year survival reduced the probability of disease relapse event.
The use of competing risks model instead of the standard models of survival in study of patients with pulmonary TB leads to a better understanding of the natural course of disease; with the evaluation of factors that affect the probability of competing events such as death and disease relapse, more accurate estimation of survival in these patient is possible allowing selection of appropriate therapeutic strategies.
